• 1
    Stojadinovic A,Leung DH,Hoos A,Jaques DP,Lewis JJ,Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002; 235: 424434.
  • 2
    Lewis JJ,Leung D,Heslin M,Woodruff JM,Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997; 15: 646652.
  • 3
    Pollack A,Zagars GK,Goswitz MS,Pollock RA,Feig BW,Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys. 1998; 42: 563572.
  • 4
    Gerrand CH,Bell RS,Wunder JS, et al. The influence of anatomic location on outcome in patients with soft tissue sarcoma of the extremity. Cancer. 2003; 97: 485492.
  • 5
    Weitz J,Antonescu CR,Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003; 21: 27192725.
  • 6
    Zagars GK,Ballo MT,Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 225 patients. Cancer. 2003; 97: 25302543.
  • 7
    Pfannschmidt J,Klode J,Muley T,Dienemann H,Hoffmann H. Pulmonary metastasectomy in patients with soft tissue sarcomas: experiences in 50 patients. Thorac Cardiovasc Surg. 2006; 54: 489492.
  • 8
    Rehders A,Hosch SB,Scheunemann P,Stoecklein NH,Knoefel WT,Peiper M. Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg. 2007; 142: 7075.
  • 9
    Liebl LS,Elson F,Quaas A,Gawad KA,Izbicki JR. Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res. 2007; 27: 28972902.
  • 10
    Alvegard TA,Sigurdsson H,Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989; 7: 15041513.
  • 11
    Chang AE,Kinsella T,Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988; 6: 14911500.
  • 12
    Gherlinzoni F,Bacci G,Picci P, et al. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol. 1986; 4: 552558.
  • 13
    Glenn J,Sindelar WF,Kinsella T, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery. 1985; 97: 316325.
  • 14
    Glenn J,Kinsella T,Glatstein E, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer. 1985; 55: 12061214.
  • 15
    Omura GA,Blessing JA,Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985; 3: 12401245.
  • 16
    Rosenberg SA,Tepper J,Glatstein E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer. 1983; 52: 424434.
  • 17
    Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350: 16471654.
  • 18
    Brodowicz T,Schwameis E,Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Semin Oncol. 2000; 4: 151160.
  • 19
    Frustaci S,Gherlinzoni F,De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 12381247.
  • 20
    Gortzak E,Azzarelli A,Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001; 37: 10961103.
  • 21
    Petrioli R,Coratti A,Correale P, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2002; 25: 468473.
  • 22
    Detsky AS,Naylor CD,O'Rourke K,McGeer AJ,L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol. 1992; 45: 255265.
  • 23
    Antman K,Crowley J,Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 12761285.
  • 24
    Edmonson JH,Ryan LM,Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 12691275.
  • 25
    Casali PG,Picci P. Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol. 2005; 17: 361365.
  • 26
    Hatala R,Keitz S,Wyer P,Guyatt G. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ. 2005; 172: 661665.
  • 27
    Eilber FC,Brennan MF,Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007; 246: 105113.
  • 28
    Ferrari A,Gronchi A,Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004; 101: 627634.